Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

• Published in: Blood Vol. 128; no. 22; p. 1226
• Main Authors: Roy, Denis-Claude, Lachance, Silvy, Roy, Jean, Walker, Irwin, Maertens, Johan, Delisle, Jean-Sebastien, Foley, Stephen Ronan, Lewalle, Philippe, Olavarria, Eduardo, Selleslag, Dominik, Rüdiger, Manfred, Velthuis, Jurjen, Gerez, Lisya, Rovers, Jeroen, Bonig, Halvard, Mielke, Stephan
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.12.2016

Introduction. Haploidentical donors may resolve the shortage of available HLA-matched donors for the treatment of patients with blood cancers in need of a hematopoietic stem cell transplantation (HSCT). However, to prevent graft-versus-host disease (GVHD), haploidentical HSCT requires alloreactive T...